## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Patent Application of

SQUIRRELL et al.

Atty. Ref.:

1498-119

Serial No.

09/763,824

Group:

1652

Filed:

February 27, 2001

Examiner:

Unassigned

For:

**NOVEL ENZYME** 

Assistant Commissioner for Patents

October 16, 2003

Washington, DC 20231

Sir:

## INFORMATION DISCLOSURE STATEMENT

M 1. PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C Fee Payment Pursuant to 37 CFR 1.97(c) 2 .(b) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3.

Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

 $\boxtimes$ A list of documents on Form PTO-1449 together with copies of each identified document.

This paper is submitted in accordance with:

SQUIRRELL et al. Serial No. 09/763,824

$\boxtimes$	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier] and
		a) The required Statement made in item 8 below; or
		b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
		a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
		b) The required Statement is stated in item 8 below.
	8.	Statement under 37 CFR 1.97(e)
		a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
		b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
$\boxtimes$	9.	Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

SQUIRRELL et al. Serial No. 09/763,824

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

## Sheet 1 of 1

INFORMATION DISCLOSURE ATTY. DOCKET NO. SERIAL NO.  CITATION 1498-119 09/763,824	
OCT 1 6 2003 & SQUIRRELL et al.	
(Use several sheet inecessary) FILING DATE GROUP	
February 27, 2001 1652	
U.S. PATENT DOCUMENTS	
*EXAMINER FILIN	G DATE
INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF APPR	ROPRIATE
	<del></del>
	<del></del>
FOREIGN PATENT DOCUMENTS	SLATION
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES	NO
	<del>-  </del>
	<u></u>
	<u> </u>
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)	200"
Arslan, et al., "Structurally Modified Firefly Luciferase. Effects of Amino Acid Substitution at Position 2 Journal of the American Chemical Society, Vol. 119, No. 45, November 12, 1997.	200 ,
Souther of the 7th order of control of the first terms of the first terms of the 7th order	
*Examiner Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considere	d. Include
copy of this form with next communication to application.  Form PTO-FB-A820 (Als	